Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | OSBP | P22059 | 1/20 | 0.31 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26999238 | 0.90 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL26999239 | 0.90 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL3488642 | 0.90 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL1929845 | 0.88 | — | — | |
| SCHEMBL4078008 | 0.88 | — | — | |
| SCHEMBL2014928 | 0.88 | MEN1 (0.31) | MEN1KMT2AOSBPOSBP2 | |
| SCHEMBL5009346 | 0.86 | MEN1 (0.31) | MEN1KMT2AOSBPOSBP2 | |
| SCHEMBL2015673 | 0.86 | MEN1 (0.31) | MEN1KMT2AOSBPOSBP2 | |
| SCHEMBL731956 | 0.86 | MEN1 (0.31) | MEN1KMT2AOSBPOSBP2 | |
| SCHEMBL27139803 | 0.79 | OSBP (0.34) | MEN1KMT2AOSBPOSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-4225749-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | Cullgen (Shanghai), Inc. (CN) | 2023-08-16 | — | — | EP | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-8598154-B2 | Pyridyl-amine fused azadecalin modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2609097-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | Corcept Therapeutics, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012027702-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | MEN1 169/4885KMT2A 2286/4885OSBP 2600/4885 |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | NR3C1, NR3C2, NR5A2 | MEN1 1404/4885KMT2A 1410/4885OSBP 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.